Ulysses is the world’s first fully automated drug discovery platform developed and operated by Arctoris based in Oxford, Boston, and Singapore.
Oxford and Zurich, September 2021. Today, IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Optimised synthetic routes are then used as input for RoboRXN, an automated platform for molecule synthesis.
Arctoris has developed Ulysses, an end-to-end automated platform for drug discovery research. The platform ensures accuracy, precision, and reproducibility by leveraging robotic experiment execution and digital data capture technologies across cell and molecular biology and biochemistry/biophysics. Experiments conducted with Ulysses generate more than 100 times more datapoints per assay compared to industry standard, leading to deeper insights and accelerated progress compared to manual methods.
The two platforms are now being combined for the first time in a research collaboration that will see new small molecule inhibitors for undisclosed targets being designed, made, tested, and analysed (DMTA) in an autonomous, closed loop approach. Concretely, IBM Research will design and synthesize novel chemical matter (Design, Make), to be profiled and evaluated by Arctoris (Test, Analyze), with the resulting data informing the subsequent iteration of the DMTA cycle.
Thomas A. Fleming, Arctoris Co-Founder & COO, explained “The future of drug discovery is computational, with AI and robotics paving the way for better treatments to reach patients sooner. We are excited about partnering with IBM Research on a world-first closed loop drug discovery project bringing together two leaders in the field of AI and robotics-powered drug discovery. This collaboration will showcase how the combination of our unique technology platforms will lead to accelerated research based on better data enabling better decisions.”
“This collaboration is a great example of the enablement that AI, Cloud and Automation can have in the space of material design. The integration between the two complementary technologies reveals how it is more and more important in R&D to turn great research into great viable products.” said Dr Teodoro Laino, Distinguished Scientist at IBM Research Europe – Zurich.
Dr Matteo Manica, Research Scientist at IBM Research Europe – Zurich, coordinating the project, stated that: “This is a unique opportunity to quantify the impact of AI and automation technologies in accelerating scientific discovery. In our collaboration, we demonstrate a pipeline to perform iterative design cycles where generative models suggest candidates that are synthesized with RoboRXN and screened with Ulysses. The data produced by Ulysses will then be used to establish a feedback loop to retrain the generative AI and improve the proposed leads in a completely data-driven fashion.”
The collaboration is currently on-going; financial terms were not disclosed.
About IBM Research
For more than seven decades, IBM Research has defined the future of information technology with more than 3,000 researchers in 16 locations across five continents. Scientists from IBM Research have produced six Nobel Laureates, 10 U.S. National Medals of Technology, five U.S. National Medals of Science, six Turing Awards, 19 inductees in the National Academy of Sciences and 20 inductees into the U.S. National Inventors Hall of Fame. For more information, please visit www.research.ibm.com/.
About Arctoris
Arctoris is a biotechnology company founded and headquartered in Oxford with additional operations in Boston and Singapore. Ulysses, the unique technology platform developed by Arctoris, enables the company to conduct its R&D – from target via hit and lead to candidate – significantly faster, and with considerably improved data quality and depth. With its robotics, Arctoris generates richer, more reliable data, enabling better decisions both in human-driven and computational drug discovery, leading to higher success rates and an accelerated progression of programs towards the clinic. Led by an experienced team, Arctoris pursues its internal pipeline of small molecule inhibitors in different indications, and also partners with other biotech and pharma companies for small molecule and biologics discovery, with partners in the US, UK, Germany, Australia, Korea, China, and several other countries.
For more information, visit www.arctoris.com.
Contact
For media or any other inquiries, please reach out to us at media@arctoris.com.